A recent study found that GFAP was associated with clinical AD incidence up to 17 years before diagnosis, while p-tau181 and NfL within 9 years in a community-based cohort, suggesting GFAP’s utility as an earlier biomarker than p-tau181 and NfL [49]. The gene discussed is NEFL; the disease is Alzheimer disease.